NICE has recommended three antimuscarinics as first-line options for female urinary incontinence in its updated guidance.
Oxybutynin, tolterodine and darifenacin are recommended first-line in their immediate-release formulations, although darifenacin is once daily.
Only if the first choice is not effective or well tolerated can alternative antimuscarinics be used – including extended release formulations – and the choice should be based on acquisition cost.
Transdermal oxybutynin is reserved for women unable to tolerate oral medication.
Today Pulse Learning launched Guideline debrief: female urinary incontinence, a CPD module which uses three typical primary care case histories to get you up-to-speed with all the new guideline recommendations most relevant to GPs.